Exploring scientific publications by firms: what are the roles of academic and corporate partners for publications in high reputation or high impact journals?

Recent research suggests that firms, particularly in science-based industries, may publish scientific articles in order to achieve strategic goals. This paper explores whether the reputation seen as publications in journals with high impact factors and the impact seen as citations of such scientific publications originating in firms benefit from R&D alliances with different types of partners. Our empirical analysis is based on a unique dataset in pharmaceutical cancer research. We analyze publications originating in biotechnology and pharmaceutical firms, with a comparison of the results to publications that do not involve a firm-based author. Our results indicate that the returns to the number of partners are decreasing and are negative after a turning point. More surprisingly, our results suggest that biotechnology and pharmaceutical firms should focus on establishing R&D alliances with pharmaceutical firms in order to increase the probability of publishing in journals with a high reputation. However, in terms of scientific impact, i.e., forward citations, publications originating in firms do not benefit from having access to different types of alliance partner